CURR - CURE Pharmaceutical Holding Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
3.4800
+0.1300 (+3.88%)
At close: 3:58PM EST
Stock chart is not supported by your current browser
Previous Close3.3500
Open3.4000
Bid0.00 x 0
Ask0.00 x 0
Day's Range3.1700 - 3.5000
52 Week Range0.5480 - 4.9000
Volume166,808
Avg. Volume53,691
Market Cap91.353M
Beta (3Y Monthly)4.46
PE Ratio (TTM)N/A
EPS (TTM)-0.42
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire20 days ago

    National Healthcare Economics and Policy Expert Ruben Jose King-Shaw Jr Joins CURE Pharmaceutical’s Board of Directors

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced Ruben Jose King-Shaw Jr. has joined its Board of Directors. King-Shaw brings significant expertise in healthcare, government and finance. King-Shaw joins the recently named chairman William (Bill) Yuan and Dr. Gene Salkind, expanding the board to six.

  • GlobeNewswirelast month

    CURE Pharmaceutical Appoints Chairman, Adds Member to its Board of Directors

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has appointed William (Bill) Yuan to Chairman of the Board and Dr. Gene Salkind to its Board of Directors.

  • GlobeNewswirelast month

    CURE Pharmaceutical To Present at Benzinga Cannabis Capital Conference

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced that it will host an investor presentation at the Benzinga Cannabis Capital Conference at the Eden Roc Miami Beach Hotel in Miami on January 16, 2019 at 5pm. “This conference is the ideal kick-off to 2019, which is set to be a landmark year for the cannabis industry,” said Rob Davidson, CEO of CURE Pharmaceutical. If you would like to schedule a meeting with CURE Pharmaceutical, please contact Ashley Ray at aray@olmsteadwilliams.com.

  • GlobeNewswire3 months ago

    CURE Pharmaceutical Secures U.S. DEA Approval to Manufacture Cannabinoid-based Pharmaceuticals

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has secured a new registration with the Drug Enforcement Administration (DEA) as a manufacturer authorized to handle Schedule 1 controlled substances. With this license, CURE will develop and manufacture cannabinoid-based pharmaceutical products using its CUREfilm™ technology at its facility in Oxnard, Calif. “This license enables CURE to translate the research findings from our collaboration with Technion – Israel Institute of Technology into potential treatments and expand our marketable product lines,” said Jessica Rousset, Chief Operating Officer of CURE Pharmaceutical.